Merck Sharp & Dohme Corp. vs. Ono Pharmaceutical Co., Ltd.
Explore the PTAB proceeding IPR2016-01218 filed by Merck Sharp & Dohme Corp. on 2016-06-29. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2016-01218
Filing Date
2016-06-29
Accorded Filing Date
2016-06-29
Institution Decision Date
โ
Last Modified Date
2018-06-26
Proceeding Type
IPR
Termination Date
2017-01-25
Trial Status
Terminated-Settled
Parties & Counsel
Petitioner
Merck Sharp & Dohme Corp.
Represented By
Jeffrey KushanPatent Owner / Respondent
Ono Pharmaceutical Co., Ltd.
Represented By
Eldora EllisonPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Terminated-Settled
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 28912 | Robert Sterne | +1 202-772-8555 |
| 29021 | Jorge Goldstein | +1 202-371-2600 |
| 32705 | Elliott Korsen | +1 609-252-4741 |
| 32831 | Tracy-Gene Durkin | +1 202-371-2600 |
| 33876 | Donald Featherstone | +1 202-772-8629 |
| 33997 | Michael Ray | +1 202-772-8569 |
| 34395 | Robert Millonig | +1 202-371-2600 |
| 35239 | Michael Lee | +1 703-628-0233 |
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 7 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 9,067,999 B1 Asserted | US Continuation / Sibling | View Official Patent → |
| ๐ฏ๐ต Japan | JP 2002194491 | Japan Counterpart | View Official Patent → |
| ๐ฏ๐ต Japan | JP 2003029846 | Japan Counterpart | View Official Patent → |
| ๐ PCT International (WIPO) | WO 2004004771 A1 | PCT World Application | View Official Patent → |
| ๐บ๐ธ United States | US 8,168,179 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 8,728,474 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 9,402,899 B2 | US Continuation / Sibling | View Official Patent → |
Merck Sharp & Dohme Corp. v. Ono Pharmaceutical Co., Ltd.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP โข ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.